Differential expression of miRNA in THP-1-derived foam cell model induced by drug-containing serum of Yimaijiangzhi decoction

Objective: To investigate the differential expression of miRNA and related biological functions and signaling pathways after the intervention of the THP-1-derived foam cell model with the drug-containing serum of Yimaijiangzhi Decoction. Methods: The experiment was divided into macrophage group, foam cell model group and Yimaijiangzhi drug-containing serum group. THP-1 cells were induced into macrophages by Fopol ester, and induced differentiated macrophages were given ox-LDL to establish foam cell model, and Yimaijiangzhi decoction rat serum was used to intervene the foam cells. Total RNA was extracted from cells in each group for miRNA sequencing, differential expression of miRNA was screened, and relevant target genes were predicted for GO analysis and KEGG analysis, protein interaction network and miRNA-target gene interaction network were established, and RT-qPCR was used to verify the possible signaling pathways for improving atherosclerosis. Result: The difference miRNA between blank group and model group was hsa-miR-302c-3p, hsa-miR-302d-3p, hsa- mir-30d-3p, hsa-mir-3189-3p, hsa-mir-374b-5p, hsa-mir-423-5p, hsa-mir-423-5p, and hsa- mir-4781-3p, hsa-mir-663a;The miRNAs of model group and Yimaijiangzhi drug-containing serum group were hsa-mir-3150a-3p, hsa-mir-7704, hsa-mir-887-3p, hsa-mir-150-5p, hsa- mir-423-5p, hsa-mir-374c-3p, hsa-mir-374c-3p, hsa-mir-374b-5p;The difference of miRNAs prediction target genes between model group and Yimaijiangzhi drug-containing serum group showed that the miRNA prediction target genes were mainly enriched in MAPK signaling pathway, ErbB signaling pathway, Hippo signaling pathway, Wnt signaling pathway and other signaling pathways. SCN1A, PRKACA, MECP2, EIF4E, SRSF1, MBNL1, PRKCA, PPARGC1A may be the potential key targets for the effect of the drug-containing serum of Yimaijiangzhi Decoction on THP-1-derived foam cells. Conclusion: hsa-mir-374c-3p, hsa- mir-423-5p, and hsa-mir-374b-5p are important miRNAs that the drug-containing serum of Yimaijiangzhi Decoction acts on foam cells. The significantly differentially expressed mirnas and significantly enriched related signaling pathways may provide new ideas for the diagnosis and treatment of atherosclerosis.

益脉降脂汤含药血清对THP-1源性泡沫细胞模型miRNA差异表达分析

目的:探讨益脉降脂汤含药血清干预THP-1源性泡沫细胞模型后差异表达miRNA及相关生物功能、信号通路。方法:实验分为巨噬细胞组、泡沫细胞模型组、益脉降脂含药血清组,以佛波酯对THP-1细胞诱导为巨噬细胞,经诱导分化的巨噬细胞给予ox-LDL建立泡沫细胞模型,以益脉降脂汤大鼠血清干预泡沫细胞。提取各组细胞Total RNA进行miRNA测序,筛选差异表达miRNA,预测相关靶基因后进行GO分析、KEGG分析,建立蛋白互作网络、miRNA-靶基因互作网络,RT-qPCR验证改善动脉粥样硬化可能信号通路。结果:空白组与模型组差异miRNA为hsa-miR-302c-3p、hsa-miR-302d-3p、hsa-miR-30d-3p、hsa-miR-3189-3p、hsa-miR-374b-5p、hsa-miR-423-5p、hsa-miR-4781-3p、hsa-miR-663a;模型组和益脉降脂含药血清组差异miRNA为hsa-miR-3150a-3p、hsa-miR-7704、hsa-miR-877-3p、hsa-miR-150-5p、hsa-miR-423-5p、hsa-miR-374c-3p、hsa-miR-374b-5p;模型组与益脉降脂含药血清组差异miRNA预测靶基因显示主要富集于MAPK信号通路、ErbB信号通路、Hippo信号通路、Wnt信号通路等信号通路;SCN1A、PRKACA、MECP2、EIF4E、SRSF1、MBNL1、PRKCA、PPARGC1A可能是益脉降脂汤含药血清向THP-1源性泡沫细胞发挥作用潜在关键靶标。结论:hsa-miR-374c-3p、hsa-miR-423-5p、hsa-miR-374b-5p是益脉降脂汤含药血清作用于泡沫细胞重要的miRNAs,差异表达显著的miRNA以及显著富集的相关信号通路可为诊断和治疗动脉粥样硬化提供新的思路。

益脉降脂汤对高脂血症患者C反应蛋白及血液流变学的影响

目的:观察自拟益脉降脂汤对高脂血症患者C反应蛋白及血液流变学的影响。方法:将120例高脂血症患者随机分为治疗组和对照组各60例。治疗组给予自拟益脉降脂汤治疗,对照组给予阿托伐他汀钙片(立普妥)治疗。观察治疗前后两组血脂、C反应蛋白及血液流变学变化情况。结果:治疗后两组均可降低TC、TG、LDL-C水平,并可上调HDL-C水平,差异有显著性意义(P均<0.01),且治疗组降低血清中TC和LDL-C水平优于对照组(P均<0.05);治疗组治疗后血浆黏度、红细胞聚集指数、纤维蛋白原、红细胞压积及C反应蛋白等指标较治疗前均明显降低(P均<0.05),对照组纤维蛋白原及C反应蛋白较治疗前降低(P均<0.05),治疗组血浆黏度、红细胞聚集指数、纤维蛋白原、红细胞压积及C反应蛋白等指标改善程度均明显优于对照组(P均<0.05)。结论:益脉降脂汤有抗动脉粥样硬化及降低血黏度作用,对预防及治疗心、脑血管疾病有重要意义。

自拟益脉降脂汤治疗高脂血症临床观察

目的观察益脉降脂汤治疗高脂血症的临床疗效。方法将120例高脂血症患者按照随机原则分为治疗组和对照组。治疗组60例,采用自拟益脉降脂汤治疗,每日1剂;对照组60例,只予阿托伐他汀钙片(立普妥)口服治疗。疗程均为3个月。观察治疗前后临床疗效及检测血清总胆固醇、血清甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇含量水平。结果治疗组和对照组血脂改善疗效总有效率分别为83.3%和86.7%,两组有显著差异(P<0.05)。治疗组及对照组总胆固醇、血清甘油三酯、低密度脂蛋白胆固醇含量水平均较治疗前显著降低,HDL-C升高(P<0.01),但是治疗组在降低甘油三酯及低密度脂蛋白胆固醇作用较对照组明显(P<0.05)。结论益脉降脂汤是有效的降脂调脂药物,值得推广应用。